Catalyst Clinical Research
Catalyst Clinical Research is recorded as a service provider in 18 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 18 of 18 trials · Latest update first
Phase 2/3 Adaptive Design, Randomized Double-blind Placebo-controlled Study to Evaluate the Safety and Efficacy of DM199 for the Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)
Sponsor Diamedica Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
First-in-human study of ATX-898 as monotherapy and in combination with other anti-neoplastic agents, in participants with advanced solid tumors
Sponsor Antares Therapeutics Inc.
- Start (EU)
- Not reported
- Latest update
- Estimated end
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated with Alzheimer’s Disease (ADEPT-4)
Sponsor Bristol-Myers Squibb Services Unlimited Company
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator’s Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (RAMP301)
Sponsor Verastem Inc.
- Start (EU)
- Latest update
- Estimated end
A Pivotal Phase 2/3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Adaptive Design Study of L-Annamycin for Injection in Combination with Cytarabine Injection Versus Placebo in Combination with Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects with Refractory/Relapsed Acute Myeloid Leukemia
Sponsor Moleculin Biotech Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared with Investigator’s Choice in HLA-A*0201 Positive Patients with Previously Untreated Advanced Uveal Melanoma
Sponsor Immunocore Limited
- Start (EU)
- Latest update
- Estimated end
Operational learnings available2 trial-level findings · Read insights
- The study randomized 378 patients at 58 sites in 14 countries.
- Tebentafusp required at least 16 hours of inpatient monitoring after dosing on Cycle 1 Days 1, 8, and 15 because of anticipated cytokine release syndrome.
These findings describe the trial, not the service provider’s performance or responsibility.
A phase 2, double-masked, randomized, multicenter, parallel group, placebo-controlled study to investigate the efficacy and safety of GAL-101, 2%, ophthalmic solution in patients with non-foveal geographic atrophy secondary to non-neovascular age-related macular degeneration: eDREAM study
Sponsor Galimedix Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 1/2 Study to Evaluate STK-012 as a Single Agent and in Combination Therapy in Subjects with Front-line Advanced NSCLC and Other Selected Indications
Sponsor Synthekine Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 1b/2, Open-Label, Randomized Platform Study Evaluating the Efficacy and Safety of AB928-Based Treatment Combinations in Patients with Metastatic Colorectal Cancer
Sponsor Arcus Biosciences Inc.
- Start (EU)
- Latest update
- Estimated end
Operational learnings available1 trial-level finding · Read insights
- Enrollment occurred across France, Italy, Republic of Korea, Spain, the United Kingdom, and the United States, with 94 of 229 enrolled participants in the United States and 69 in the Republic of Korea.
These findings describe the trial, not the service provider’s performance or responsibility.
A Phase 1/2 Trial of TER-2013 in Patients with Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
Sponsor Terremoto Biosciences Inc.
- Start (EU)
- Not reported
- Latest update
- Estimated end
A Phase 3 Study to Evaluate Zimberelimab (AB122) Combined with Domvanalimab (AB154) Compared to Pembrolizumab in Front-Line, PD-L1-High, Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Sponsor Arcus Biosciences Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE).
Sponsor Pmv Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
An Open-Label, Dose Escalation and Dose Expansion Trial Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered CA-4948 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma
Sponsor Curis Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Multi-center, Randomized Withdrawal and Long-Term Extension Study of Ampreloxetine for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Participants with Multiple System Atrophy
Sponsor Theravance Biopharma Ireland Limited
- Start (EU)
- Latest update
- Estimated end
An Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of ZYN002 Administered as a Transdermal Gel to Children, Adolescents and Young Adults with Fragile X Syndrome
Sponsor Harmony Biosciences Management Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 1/2A, Open Label Dose Escalation and Cohort Expansion Study of Orally Administered CA-4948 (IRAK4i) as a Monotherapy in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome
Sponsor Curis Inc.
- Start (EU)
- Latest update
- Estimated end
A Randomized, Double-Blind, Placebo-Controlled Multiple-Center, Efficacy and Safety Study of ZYN002 Administered as a Transdermal Gel to Children, Adolescents, and Young Adults with Fragile X Syndrome - RECONNECT
Sponsor Harmony Biosciences Management Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 1/2 Study of EPI-7386 in Combination with Enzalutamide Compared with Enzalutamide Alone in Subjects with Metastatic Castration-Resistant Prostate Cancer
Sponsor Essa Pharma Inc.
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Catalyst Clinical Research?
The 2026-10-09 snapshot links Catalyst Clinical Research to 18 distinct CTIS trials. Recorded services include Clinical monitoring, Safety reporting & pharmacovigilance, Regulatory services, Project management, among 11 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Catalyst Clinical Research?
The most frequently recorded therapeutic areas are Solid Tumor Oncology, Gastroenterology, Gynecology, Neurology. Recorded phases include Phase 2, Phase 3, Phase 1. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Catalyst Clinical Research conducted?
The linked trials record locations in 21 countries, including Spain, France, Italy, Poland, Belgium. These are trial locations, not confirmed office locations or countries where Catalyst Clinical Research delivered services.
What can this page tell me about Catalyst Clinical Research's trial experience?
Browse 18 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 2 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 2 recorded name variants under Catalyst Clinical Research. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Catalyst Clinical Research
- Catalyst Clinical Research LLC